HomeComparePAIOF vs NOBL

PAIOF vs NOBL: Dividend Comparison 2026

PAIOF yields 20000.00% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PAIOF wins by $52481917574412746752.00M in total portfolio value
10 years
PAIOF
PAIOF
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full PAIOF calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — PAIOF vs NOBL

📍 PAIOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPAIOFNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PAIOF + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PAIOF pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PAIOF
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, PAIOF beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PAIOF + NOBL for your $10,000?

PAIOF: 50%NOBL: 50%
100% NOBL50/50100% PAIOF
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PAIOF buys
0
NOBL buys
0
No recent congressional trades found for PAIOF or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPAIOFNOBL
Forward yield20000.00%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$52481917574412746752.00M$22.9K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00$249.78
Total dividends collected$52448189483771600896.00M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: PAIOF vs NOBL ($10,000, DRIP)

YearPAIOF PortfolioPAIOF Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$2,010,700$2,000,000.00$10,917$217.08+$2.00MPAIOF
2$377,983,225$375,831,775.70$11,903$221.48+$377.97MPAIOF
3$66,433,479,469$66,029,037,418.28$12,962$225.68+$66433.47MPAIOF
4$10,916,985,471,987$10,845,901,648,955.73$14,099$229.68+$10916985.46MPAIOF
5$1,677,384,363,769,318$1,665,703,189,314,291.80$15,319$233.49+$1677384363.75MPAIOF
6$240,985,175,079,139,100$239,190,373,809,905,920.00$16,628$237.10+$240985175079.12MPAIOF
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$18,033$240.53+$32373573631143.68MPAIOF
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$19,539$243.78+$4066766648320630.00MPAIOF
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$21,154$246.86+$477730483406513344.00MPAIOF
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$22,884$249.78+$52481917574412746752.00MPAIOF

PAIOF vs NOBL: Complete Analysis 2026

PAIOFStock

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.

Full PAIOF Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this PAIOF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PAIOF vs SCHDPAIOF vs JEPIPAIOF vs OPAIOF vs KOPAIOF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.